Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
转化生长因子-β (TGFβ) 抑制剂 SAR439459 作为单一疗法和与 cemiplimab 联合治疗晚期实体肿瘤患者的 I 期临床研究的生物标志物和药效学活性
期刊:Journal of Clinical and Translational Science
影响因子:3.1
doi:10.1111/cts.13736
Debbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, Matteo Simonelli, Bernard Doger, Ivan Borbath, Marcus O Butler, Tina Cheng, Patricia Martin Romano, Elvire Pons-Tostivint, Massimo Di Nicola, Giuseppe Curigliano, Min-Hee Ryu, Alejo Rodriguez-Vida, Dirk Schadendorf, Elena Garralda, Giovanni Abbade
